<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708041</url>
  </required_header>
  <id_info>
    <org_study_id>V503-069</org_study_id>
    <secondary_id>2020-003736-24</secondary_id>
    <secondary_id>V503-069</secondary_id>
    <nct_id>NCT04708041</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)</brief_title>
  <official_title>A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen With Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared With a Standard 3-dose Regimen in 16- to 26-Year Old Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 96-month safety and immunogenicity study conducted in boys and girls 9 to 14 years&#xD;
      of age and in young women 16 to 26 years of age. From this study, the goal is to establish&#xD;
      that the investigational extended 2-dose regimens (0, 12 months; 0, 24 months; 0, 36 months;&#xD;
      and 0, 60 months) studied in boys and girls 9 to 14 years of age are generally safe and&#xD;
      immunogenic, with an antibody response that is not inferior to that observed in young women&#xD;
      16 to 26 years of age who receive the standard 3-dose regimen of 9-valent human&#xD;
      papillomavirus (9vHPV) vaccine at 0, 2, and 6 months (i.e., the population and dose regimen&#xD;
      used to establish 9vHPV vaccine efficacy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">June 18, 2029</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2029</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers of Anti-Human Papilloma Virus Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 as Measured by Competitive Luminex Immunoassay</measure>
    <time_frame>4 weeks post last vaccination (Up to ~Month 61)</time_frame>
    <description>Serum antibody titers for human papilloma virus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using competitive luminex immunoassay (cLIA). The geometric mean titer (GMT) for each HPV type will be reported in milli Merck units/mL (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to 5 days post vaccination</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants with injection-site AEs (erythema/redness, pain and swelling) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Systemic Adverse Event</measure>
    <time_frame>Up to 15 days post vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants with a systemic AE will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Vaccine-Related Adverse Event</measure>
    <time_frame>Entire study period (Up to ~Month 96)</time_frame>
    <description>A serious adverse event (SAE) is defined as one that results in death, is life threatening, or requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or other important medical event that may require medical intervention. An SAE that is judged by the investigator to be related to the study vaccine is defined as a vaccine-related SAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58</measure>
    <time_frame>4 weeks post last vaccination</time_frame>
    <description>Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The percentage of participants who are seropositive (analysis population Cohorts 1 through 5 only) for each HPV type will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (Cohorts 1 to 5) of Anti HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58</measure>
    <time_frame>12 months post last vaccination</time_frame>
    <description>Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The GMT for each HPV type (analysis population Cohorts 1 through 5 only) will be reported in mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58</measure>
    <time_frame>12 months post last vaccination</time_frame>
    <description>Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The percentage of participants who are seropositive (analysis population Cohorts 1 through 5 only) for each HPV type will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers ( Cohorts 1 to 5) of Anti HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58</measure>
    <time_frame>24 months post last vaccination</time_frame>
    <description>Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The GMT for each HPV type (analysis population Cohorts 1 through 5 only) will be reported in mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58</measure>
    <time_frame>24 months post last vaccination</time_frame>
    <description>Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The percentage of participants who are seropositive (analysis population Cohorts 1 through 5 only) for each HPV type will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers ( Cohorts 1 to 5) of Anti HPV Types 6, 11, 16, 18, 31, 33, 45, 52 , and 58</measure>
    <time_frame>36 months post last vaccination</time_frame>
    <description>Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The GMT for each HPV type (analysis population Cohorts 1 through 5 only) will be reported in mMU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58</measure>
    <time_frame>36 months post last vaccination</time_frame>
    <description>Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The percentage of participants who are seropositive (analysis population Cohorts 1 through 5 only) for each HPV type will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Papillomavirus Infections</condition>
  <arm_group>
    <arm_group_label>Cohort 0: 1 Dose of 9vHPV Vaccine (previous 1-dose recipients)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 to 15 year old girls and boys (who previously received 1 dose of 9vHPV vaccine) receive a second dose of 9vHPV vaccine at Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: 2 Doses of 9vHPV Vaccine Given 12 Months Apart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 to 14 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 2 Doses of 9vHPV Vaccine Given 24 Months Apart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 to 13 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Months 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: 2 Doses of 9vHPV Vaccine Given 36 Months Apart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 to 12 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 36.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: 2 Doses of 9vHPV Vaccine Given 60 Months Apart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 to 10 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: 3 Doses of 9vHPV Vaccine Given Over a 6-Month Period</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16 to 26 year old young women receive 3 dose regimen of 9vHPV vaccine at Day 1, Month 2 and Month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>9vHPV vaccine</intervention_name>
    <description>9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection</description>
    <arm_group_label>Cohort 0: 1 Dose of 9vHPV Vaccine (previous 1-dose recipients)</arm_group_label>
    <arm_group_label>Cohort 1: 2 Doses of 9vHPV Vaccine Given 12 Months Apart</arm_group_label>
    <arm_group_label>Cohort 2: 2 Doses of 9vHPV Vaccine Given 24 Months Apart</arm_group_label>
    <arm_group_label>Cohort 3: 2 Doses of 9vHPV Vaccine Given 36 Months Apart</arm_group_label>
    <arm_group_label>Cohort 4: 2 Doses of 9vHPV Vaccine Given 60 Months Apart</arm_group_label>
    <arm_group_label>Cohort 5: 3 Doses of 9vHPV Vaccine Given Over a 6-Month Period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Boys and Girls 9 to 15 Years:&#xD;
&#xD;
        - Must not have had coitarche and does not plan on becoming sexually active during the&#xD;
        vaccination period&#xD;
&#xD;
        Women 16 to 26 Years:&#xD;
&#xD;
          -  Has never had a Papanicolaou (Pap) test or only had normal Pap test results&#xD;
&#xD;
          -  A lifetime history of 0 to 4 male and/or female sexual partners&#xD;
&#xD;
        Cohort 0 Participants:&#xD;
&#xD;
        - Received 1 dose of 9vHPV vaccine at least 1 year prior to enrollment and did not receive&#xD;
        a second dose of any HPV vaccine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Participants:&#xD;
&#xD;
          -  Known allergy to any vaccine component&#xD;
&#xD;
          -  History of severe allergic reaction that required medical intervention&#xD;
&#xD;
          -  Thrombocytopenia or any coagulation disorder&#xD;
&#xD;
          -  Females only: participant is pregnant or expecting to donate eggs during day 1 through&#xD;
             month 7&#xD;
&#xD;
          -  Currently immunocompromised, or been diagnosed with immunodeficiency&#xD;
&#xD;
          -  Had a splenectomy&#xD;
&#xD;
          -  Receiving or has received immunosuppressive therapies within the last year&#xD;
&#xD;
          -  Received any immunoglobulin product or blood-derived product within 3 months&#xD;
&#xD;
          -  Has received more than 1 dose of an HPV vaccine (Cohort 0)&#xD;
&#xD;
          -  Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial&#xD;
             (Cohorts 1-5)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy male and female participants between the ages of 9 to 15 years (inclusive) and female participants between the ages of 16 and 26 years (inclusive) will be enrolled in this study.</gender_description>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaiser Permanente Daly City ( Site 0044)</name>
      <address>
        <city>Daly City</city>
        <state>California</state>
        <zip>94015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>510-267-7534</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland ( Site 0020)</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>510-267-7534</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Roseville ( Site 0047)</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>510-267-7534</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Sacramento ( Site 0043)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>510-267-7534</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente South Sacramento ( Site 0045)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>510-267-7534</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Jose ( Site 0046)</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>510-267-7534</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Santa Clara ( Site 0042)</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>510-267-7534</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research ( Site 0022)</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>619-660-9068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research for Health Improvement, LLC-Pediatrics ( Site 0007)</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>239-230-2021</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tribe Clinical Research, LLC ( Site 0010)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>864-372-3970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center ( Site 0032)</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-856-3784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Bend Clinical Research ( Site 0025)</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>361-288-4668</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch-Sealy Institute for Vaccine Sciences Clinical Trials Program ( Si</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>409-772-5278</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MultiCare Rockwood Cheney Clinic ( Site 0038)</name>
      <address>
        <city>Cheney</city>
        <state>Washington</state>
        <zip>99004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-903-6393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Centro de Investigación Clínica CIC ( Site 0157)</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <zip>050021</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>573104262877</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Atención e Investigación Médica SAS - CAIMED CHIA ( Site 0151)</name>
      <address>
        <city>Chia</city>
        <state>Cundinamarca</state>
        <zip>250001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573158187608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAIMED México ( Site 0207)</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>55-6583-4651</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AINPAD ( Site 0204)</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58350</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+524433147522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad biomedica avanzada monterrey ( Site 0203)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8183186936</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan (</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97130</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+52 999 290 02 66</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny-Klinika Pediatrii i Chorob Infekcyjnych ( Site 0556)</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-369</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48717703150</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gravita Diagnostyka i Leczenie Nieplodnosci ( Site 0555)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48 601272443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ALERGO-MED Specjalistyczna Przychodnia Lekarska ( Site 0557)</name>
      <address>
        <city>Tarnow</city>
        <state>Malopolskie</state>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>(14) 639-30-12</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jerzy Brzostek Prywatny Gabinet Lekarski ( Site 0553)</name>
      <address>
        <city>Debica</city>
        <state>Podkarpackie</state>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48604997342</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit_Do not use - Duplicate facility ( Site 0351)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>27119899720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TREAD Research ( Site 0354)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27219317825</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital ( Site 0653)</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886423592525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 0651)</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886-2-23123456 ext 71525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation.Linkou Branch ( Site 0652)</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>88633281200</phone>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Teppler H, Bautista O; Thomas Group, Flores S, McCauley J, Luxembourg A. Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals. Contemp Clin Trials. 2021 Jun;105:106403. doi: 10.1016/j.cct.2021.106403. Epub 2021 Apr 12.</citation>
    <PMID>33857679</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

